Temelimab

Temelimab
Monoclonal antibody
Type?
Legal status
Legal status
  • Experimental

Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.[1] As of 2023, it is also being studied for cognitive impairment in long COVID.[4]

References

  1. 1 2 Irfan SA, Murtaza M, Ahmed A, Altaf H, Ali AA, Shabbir N, Baig MM (May 2022). "Promising role of temelimab in multiple sclerosis treatment". Multiple Sclerosis and Related Disorders. 61: 103743. doi:10.1016/j.msard.2022.103743. PMID 35344907. S2CID 247489555.
  2. ↑ Mouliou DS, Dardiotis E (August 2022). "Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?". Multiple Sclerosis and Related Disorders. 64: 103938. doi:10.1016/j.msard.2022.103938. PMC 9169463. PMID 35717898.
  3. ↑ Kornmann G, Curtin F (December 2020). "Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review". Drug Safety. 43 (12): 1287–1296. doi:10.1007/s40264-020-00988-3. PMID 32794123. S2CID 221126453.
  4. ↑ Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, et al. (2023-03-09). "Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative". Frontiers in Immunology. 14: 1129459. doi:10.3389/fimmu.2023.1129459. PMC 10034329. PMID 36969241.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.